Does Pomegranate Blood Flow Randomized Trial work?

Updated June 2026

Quick Answer

Pomegranate Blood Flow Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Conclusion Under tightly controlled dietary conditions, a single dose of pomegranate extract did not reduce post-OCC TMAO responses in the overall cohort.

Key Takeaways

  • 01Conclusion Under tightly controlled dietary conditions, a single dose of pomegranate extract did not reduce post-OCC TMAO responses in the overall cohort. [Haarhuis JE (2026)]
  • 02Introduction Polyphenol-rich pomegranate extract has been shown to inhibit microbial trimethylamine (TMA) production from L-carnitine. [Haarhuis JE (2026)]
  • 03Previous clinical studies have examined effects of polyphenol-rich interventions on fasting trimethylamine N-oxide (TMAO) concentrations but have not assessed pharmacokinetic TMAO responses following an oral carnitine challenge (OCC). [Haarhuis JE (2026)]
  • 04PSO significantly reduced histological injury: Median total injury score was 9 (7-11) in IR, 6 (4-8) in IR + PSO low, and 3 (2-5) in IR + PSO high ( P < 0.001). [Altimimi MLM (2026)]
The current Migaku evidence database contains 2 reusable source documents for Pomegranate Blood Flow Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - Conclusion Under tightly controlled dietary conditions, a single dose of pomegranate extract did not reduce post-OCC TMAO responses in the overall cohort. [Haarhuis JE (2026); evidence level 2] - Introduction Polyphenol-rich pomegranate extract has been shown to inhibit microbial trimethylamine (TMA) production from L-carnitine. [Haarhuis JE (2026); evidence level 2] - Previous clinical studies have examined effects of polyphenol-rich interventions on fasting trimethylamine N-oxide (TMAO) concentrations but have not assessed pharmacokinetic TMAO responses following an oral carnitine challenge (OCC). [Haarhuis JE (2026); evidence level 2] - PSO significantly reduced histological injury: Median total injury score was 9 (7-11) in IR, 6 (4-8) in IR + PSO low, and 3 (2-5) in IR + PSO high ( P < 0.001). [Altimimi MLM (2026); evidence level 4] - Multivariable logistic regression showed that PSO treatment was associated with lower odds of severe IR injury (odds ratio: 0.40, 95% confidence interval: 0.18-0.90). [Altimimi MLM (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Effect of a polyphenol-rich pomegranate extract on plasma trimethylamine N-oxide levels following an oral carnitine challenge: a randomized controlled crossover trial in healthy adults.
  2. Effects of pomegranate seed oil on lower-extremity ischemia-reperfusion damage: Insights into oxidative stress, inflammation, and cell death.